Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01557257 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics Study of ALO-02 and OxyContin
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01557257 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 13 participants.
The verdict
NCT01557257, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
To characterize the single- and multiple-dose pharmacokinetics of oxycodone following the administration of ALO-02 40 Mg Twice Daily, ALO-02 80 Mg Once Daily or Oxycontin 40 Mg Twice Daily in Healthy Volunteers
Interventions
- DRUG OxyContin
- DRUG ALO-02
- DRUG Naltrexone block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01557257
The ClinicalTrials.gov registry entry for NCT01557257 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which OxyContin is the first listed.
NCT01557257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01557257 about?
NCT01557257 is a clinical study titled "Pharmacokinetics Study of ALO-02 and OxyContin". To characterize the single- and multiple-dose pharmacokinetics of oxycodone following the administration of ALO-02 40 Mg Twice Daily, ALO-02 80 Mg Once Daily or Oxycontin 40 Mg Twice Daily in Healthy Volunteers
What is the current status of trial NCT01557257?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2012-03. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01557257?
The interventions under investigation include: OxyContin (DRUG), ALO-02 (DRUG), Naltrexone block (DRUG).
Who is sponsoring clinical trial NCT01557257?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.